PriceTargets.com logo

CalciMedica - CALC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.00
  • Forecasted Upside: 1,480.74%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.82 As of 03/18/2026 05:00 PM ET
▼ -0.0111 (-1.33%)

This chart shows the closing price for CALC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CalciMedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALC

Analyst Price Target is $13.00
▲ +1,480.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CalciMedica in the last 3 months. The average price target is $13.00, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 1,480.74% upside from the last price of $0.82.

This chart shows the closing price for CALC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in CalciMedica. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/5/2026OppenheimerLower TargetOutperform ➝ Outperform$20.00 ➝ $10.00
1/29/2026HC WainwrightReiterated RatingBuy ➝ Neutral
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/4/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $16.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
7/10/2024OppenheimerBoost TargetOutperform ➝ Outperform$14.00 ➝ $20.00
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
6/28/2024Singular ResearchUpgradeModerate Buy
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$14.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
2/16/2024JonesTradingInitiated CoverageBuy$22.00
2/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
1/29/2024HC WainwrightReiterated RatingBuy$20.00
11/13/2023OppenheimerReiterated RatingOutperform ➝ Outperform$14.00
3/24/2023OppenheimerInitiated CoverageOutperform
(Data available from 3/18/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2025
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2026
  • 0 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2026

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
CalciMedica logo
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Read More

Today's Range

Now: $0.82
Low: $0.77
High: $0.87

50 Day Range

MA: $2.00
Low: $0.51
High: $5.85

52 Week Range

Now: $0.82
Low: $0.46
High: $7.20

Volume

398,128 shs

Average Volume

532,006 shs

Market Capitalization

$12.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of CalciMedica?

The following Wall Street research analysts have issued research reports on CalciMedica in the last year: HC Wainwright, Oppenheimer Holdings, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CALC.

What is the current price target for CalciMedica?

0 Wall Street analysts have set twelve-month price targets for CalciMedica in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 1,508.3%. HC Wainwright has the highest price target set, predicting CALC will reach $16.00 in the next twelve months. Oppenheimer Holdings, Inc. has the lowest price target set, forecasting a price of $10.00 for CalciMedica in the next year.
View the latest price targets for CALC.

What is the current consensus analyst rating for CalciMedica?

CalciMedica currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CALC, but not buy more shares or sell existing shares.
View the latest ratings for CALC.

What other companies compete with CalciMedica?

Other companies that are similar to CalciMedica include Instil Bio, Metagenomi, Acrivon Therapeutics, Lipocine and OnKure Therapeutics. Learn More about companies similar to CalciMedica.

How do I contact CalciMedica's investor relations team?

CalciMedica's physical mailing address is 203 REDWOOD SHORES PARKWAY SUITE 620, REDWOOD CITY CA, 94065. The company's listed phone number is 858-952-5500 and its investor relations email address is [email protected]. The official website for CalciMedica is www.graybug.vision. Learn More about contacing CalciMedica investor relations.